Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Kevin Hrusovsky, Nicolas Barthelemy

Premium

Quanterix has named Kevin Hrusovsky executive chairman of its board of directors.
Hrusovsky will replace Martin Madaus, who gave up his chairman seat to be chairman and CEO of Ortho-Clinical Diagnostics but who will remain on the Quanterix board.

Hrusovsky formerly was president of PerkinElmer Life Sciences & Technology. He was CEO of Caliper Life Sciences and joined PerkinElmer after that firm acquired Caliper in 2011 for $600 million. Hrusovsky also previously served as CEO of Zymark, and he was president of FMC Corporation's Pharmaceuticals and International Agricultural Products.


Repligen has appointed Nicolas Barthelemy to its board of directors. He spent the last nine years at Life Technologies, until Thermo Fisher Scientific acquired it, most recently serving as Life Tech's president of global commercial operations. Prior to joining Life Tech, he was vice president of manufacturing at Biogen and also the general manager for the company's manufacturing organization.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.